Noninvasive assessment of liver damage in chronic hepatitis B

Table 4 Statistical diagnostic measures and Kappa test results of neutrophil-lymphocyte and aspartate aminotransferase/platelet ratio score in the detection of significant fibrosis and cirrhosis

Variable	Diagnostic measures					Kappa test
	SEN (95%CI)	SPE (95%CI)	PPR (95%CI)	NPR (95%CI)	AR (95%CI)	κ	P value
Significant fibrosis
N/L ( ≤ 2.18)	0.73 (0.59-0.84)	0.41 (0.25-0.59)	0.67 (0.53-0.78)	0.48 (0.29-0.67)	0.61 (0.50-0.71)	0.143	0.174
APRI (> 0.56)	0.65 (0.51-0.78)	0.56 (0.38-0.73)	0.71 (0.56-0.83)	0.50 (0.33-0.67)	0.62 (0.51-0.72)	0.209	0.048
Cirrhosis
N/L (> 2.58)	0.38 (0.14-0.68)	0.87 (0.77-0.64)	0.33 (0.12-0.62)	0.89 (0.80-0.95)	0.80 (0.70-0.88)	0.238	0.024
APRI (> 1.01)	0.62 (0.36-0.86)	0.74 (0.62-0.83)	0.29 (0.13-0.49)	0.92 (0.82-0.97)	0.72 (0.61-0.81)	0.238	0.011

SEN: Sensitivity; SPE: Specifity; PPR: Positive predictive rate; NPR: Negative predictive rate; AR: Accuracy rate; APRI: Aspartate aminotransferase/platelet ratio index; N/L: Neutrophil-lymphocyte ratio.